J Breast Cancer.  2013 Jun;16(2):244-244. 10.4048/jbc.2013.16.2.244.

Prominin-1 and Its Role in Tumor Progression and Assessment of Clinical Prognosis in Systemic Malignancies

• Kapoor S

• KMID: 2286408
• DOI: http://doi.org/10.4048/jbc.2013.16.2.244

Abstract

No abstract available.

MeSH Terms

Antigens, CD
Glycoproteins
Peptides
Prognosis
Antigens, CD
Glycoproteins
Peptides

Reference

1. Di Bonito M, Collina F, Cantile M, Camerlingo R, Cerrone M, Marra L, et al. Aberrant expression of cancer stem cells marker prominin-1 in low-grade tubulobular breast carcinoma: a correlative study between qRT-PCR, flow-cytometric and immunohistochemistry analysis. J Breast Cancer. 2012; 15:15–23.

2. Wang K, Xu J, Zhang J, Huang J. Prognostic role of CD133 expression in colorectal cancer: a meta-analysis. BMC Cancer. 2012; 12:573.

3. Park JJ, Kwon JH, Oh SH, Choi J, Moon CM, Ahn JB, et al. Differential expression of CD133 based on microsatellite instability status in human colorectal cancer. Mol Carcinog. Epub 2012 Oct 12. DOI: http://dx.doi.org/10.1002/mc.21971.

4. Reggiani Bonetti L, Migaldi M, Caredda E, Boninsegna A, Ponz De Leon M, Di Gregorio C, et al. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients. Scand J Gastroenterol. 2012; 47:1211–1217.

5. Lonnroth C, Andersson M, Nordgren S, Lundholm K. Downregulation of prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment. Int J Oncol. 2012; 41:15–23.

6. Reyes EE, Kunovac SK, Duggan R, Kregel S, Griend DJ. Growth kinetics of CD133-positive prostate cancer cells. Prostate. 2013; 73:724–733.

7. Zhang J, Guo X, Chang DY, Rosen DG, Mercado-Uribe I, Liu J. CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol. 2012; 25:456–464.